On 18 July 2025, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted approval for the first-ever adrenaline (epinephrine) nasal spray, branded EURneffy, for emergency treatment of anaphylaxis in adults and children weighing 30 kg or more.
Until now, adrenaline has only been available in the UK via auto‑injector pens (AAIs), such as EpiPen or Jext. EURneffy marks an amazing major milestone by introducing a needle‑free, intranasal delivery option that could improve accessibility and reduce delays in treatment
How does EURneffy work?
• Single‑dose 2 mg spray: delivers its entire contents in one activation.
• Designed to work even if the nose is congested, making it suitable during colds or allergy flare-ups
• Longer shelf life (~30 months) and better temperature stability than traditional AAIs, potentially enhancing usability and reducing wastage
Patients must be properly trained before they can use it. For example, pressing the plunger before inserting into the nostril will prematurely release the dose and render it unusable.
Who is it designed for?
EURneffy is approved for adults and children weighing at least 30 kg (that's approximately 66 lb), the same threshold as standard for adult auto‑injectors.
It's intended for the emergency treatment of anaphylaxis caused by food, insect stings or bites, medications, and other triggers, including exercise‑induced or idiopathic episodes
Why it matters
Reduces barriers to prompt adrenaline use, especially for those with needle phobia or reluctance to carry bulky injectors
Speeds up administration: delaying the use of adrenaline is known to worsen outcomes in anaphylactic emergencies
Supports NHS effectiveness: longer shelf life and easier storage could prove more cost‑effective overall
Safety profile & instructions
Clinical trial data (over 700 participants) showed EURneffy achieved comparable blood levels and blood pressure effects to intramuscular auto‑injectors
Common side effects, especially if a second dose (total 4 mg) is given, include:
throat irritation
headache
nasal discomfort or tingling
feeling jittery
Healthcare providers advise that two doses should always be carried. If symptoms persist or recur after 10 minutes, a second dose may be administered in the same nostril.
Hospital attendance remains essential even if symptoms improve.
Patient advice & next steps
Doctors will soon be able to prescribe EURneffy, subject to price and reimbursement agreements with the NHS Department of Health and Social Care.
Availability is expected in the latter part of the third quarter of the year.
Patients previously hesitant to use AAIs may find EURneffy a more acceptable alternative. Nonetheless, auto‑injectors remain the first‑line treatment and should still be carried and used when available.
Pharmaceutical Technology
Education and training are absolutely vital. The MHRA emphasises familiarisation with both AAI and nasal spray use, and reporting any suspected side‑effects via the Yellow Card scheme.
The UK’s approval of EURneffy represents a major advance in allergy care, a needle‑free, easy‑to‑carry emergency option for managing life‑threatening allergic reactions.
It promises greater accessibility and reduced hesitation in using adrenaline when every second counts. While AAIs remain essential, EURneffy could redefine preparedness for many living with severe allergy risks in Britain.